$CTOR News

Last published 10h ago

10h agoCTXR CTORCitius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in LondonPR NewswireCitius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
2w agoCTORCITIUS ONCOLOGY, INC. - PRESS RELEASE, DATED OCTOBER 26, 2026Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
2w agoCTOR CTXRCitius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026PR NewswireCRANFORD, N.J., Oct. 26, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of
1mo agoCTXR CTORCitius Pharmaceuticals to Participate in October 2026 Investor ConferencesPR NewswireChairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the 2026 Maxim Growth Summit and the ThinkEquity ConferenceCRANFORD, N.J., Oct. 12, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc.
2mo agoCTXR CTORCitius Pharmaceuticals to Participate in September 2026 Investor ConferencesPR NewswireCitius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
2mo agoCTXR CTORCitius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business UpdatePR Newswire$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ®$17 million in cash and cash equivalents as of June 30, 2026Expanded LYMPHIR commercial and medical affairs
2mo agoCTOR CTXRCitius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business UpdatePR Newswire$7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR® launch progressesStrong institutional demand drives growth in total vials ordered and number of institutions orderingLYMPHIR ordered by 44
3mo agoCTOR CTXRCitius Oncology Expands Board with Appointment of Independent Director Jonathan PeriPR NewswireCRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc.
3mo agoCTORCitius Oncology Reports Strong Commercial Momentum for its Cancer TreatmentPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius...
3mo agoCTORCitius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market AdoptionPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius...
5mo agoCTOR CTXRCitius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic MalignanciesPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius...
5mo agoCTORCitius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual MeetingPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius...
6mo agoCTOR CTXRCitius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business UpdatePR NewswireCitius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius...
6mo agoCTXR CTORCitius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business UpdatePR NewswireCitius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
6mo agoCTORCitius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® CommercializationPR NewswireCitius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and...
6mo agoCTOR CTXRCitius Oncology Ships First International Order of LYMPHIR™ to EuropePR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius...
7mo agoCTOR CTXRCitius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical DevelopmentPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius...
7mo agoCTOR CTXRCitius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma ExpertsPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius...
8mo agoCTOR CTXRCitius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic CancersPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius...
8mo agoCTOR CTXRCitius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell LymphomaPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius...
9mo agoCTOR CTXRCitius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™PR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
9mo agoCTXR CTORCitius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™PR NewswireCitius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
9mo agoCTORCitius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with UnipharPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
10mo agoONCY BCTX GLSI CTOR+1How $594B in Precision Tech is Cracking the Metastatic Cancer CodePR NewswireThe global cancer drugs market is surging toward $594.3 billion by 2035 as high-tech immunotherapies begin to replace traditional chemotherapy[1]....
10mo agoCTXR CTORCitius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business UpdatePR NewswireCitius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
10mo agoCTOR CTXRCitius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business UpdatePR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
11mo agoCTOR CTXRCitius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq RulesPR NewswireCitius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius...
11mo agoCTOR CTXRCitius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq RulesPR NewswireCitius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius...
11mo agoCTOR CTXRCitius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-KimPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
11mo agoAMGN CTOR FOLD SNGX+1Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging PopulationsGlobeNewswireAUSTIN, Texas, Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Chronic illnesses and rare disorders among older Americans represent a rapidly intensifying challenge for the U.S. healthcare system, with
11mo agoCTOR CTXRCitius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)PR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
11mo agoCTOR CTXRCitius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual MeetingPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
11mo agoCTOR CTXRCitius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI IntegrationPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
1y agoCTORCitius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial LaunchPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
1y agoCTXR CTORCitius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 ConferencesPR NewswireCitius Pharmaceuticals, Inc. (Nasdaq: CTXR) and Citius Oncology, Inc. (Nasdaq: CTOR) today announced that management will be participating in three...
1y agoCTOR CTXRCitius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™PR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
1y agoGTBP LXEO ANIX TEM+1Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034PR NewswireOhio State researchers recently solved a critical mystery explaining why some cancer immunotherapies fail[1], while a University of Chicago team...
1y agoCTORCitius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern EuropePR NewswireCitius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and...
1y agoCTORCitius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private PlacementPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
1y agoCTOR CTXRCitius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private PlacementPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
1y agoCTOR CTXRCitius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR LaunchPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
1y agoCTORCitius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business UpdatePR NewswireCitius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and...
1y agoSNGX AMGN FOLD TNXP+1Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for InnovatorsPR NewswireAs the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults. The...
1y agoCTOR CTXRCitius Oncology Announces Closing of $9.0 Million Public OfferingPR NewswireCitius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq:...
1y agoCTOR CTXRCitius Oncology Announces Pricing of $9.0 Million Public OfferingPR NewswireCitius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq:...
1y agoCTOR CTXRCitius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with CencoraPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), today announced ...
1y agoONCY TEVA CTOR ADCT+1The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?PR NewswireUSA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in...
1y agoCTOR CTXRCitius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025PR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
1y agoONCY TPST CTOR CTXR+1After Major Oncology Conference, All Eyes Turn to Industry InnovationPR NewswireAfter the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and...
1y agoCTOR CTXR CAHCitius Oncology Enters into Distribution Services Agreement with Cardinal HealthPR NewswireCitius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...